<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD00830000_1</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>P10635</UniProt_ID>
  <Seq_Length>497</Seq_Length>
  <Molecule_Weight>55769</Molecule_Weight>
  <KEGG_ID>hsa:1565</KEGG_ID>
  <Orthology_ID>K17712</Orthology_ID>
  <Function_Summary>Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.</Function_Summary>
  <Catalytic_Mechanism>RH + reduced flavoprotein + O(2) = ROH + oxidized flavoprotein + H(2)O.</Catalytic_Mechanism>
  <Pfam_ID>PF00067:p450</Pfam_ID>
  <Allosteric_Activator_Count>0</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>0</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>0</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>CYPIID6</Alias>
      <Alias>Debrisoquine 4-hydroxylase</Alias>
      <Alias>Cytochrome P450-DB1</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Catalysis of the incorporation of one atom from molecular oxygen into a compound and the reduction of the other atom of oxygen to water.</Detail>
      <Keyword>Monooxygenase activity</Keyword>
      <Ontology_ID>GO:0004497</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Any molecular entity that serves as an electron acceptor and electron donor in an electron transport system.</Detail>
      <Keyword>Electron carrier activity</Keyword>
      <Ontology_ID>GO:0009055</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a drug, any naturally occurring or synthetic substance, other than a nutrient, that, when administered or applied to an organism, affects the structure or functioning of the organism; in particular, any such substance used in the diagnosis, prevention, or treatment of disease.</Detail>
      <Keyword>Drug binding</Keyword>
      <Ontology_ID>GO:0008144</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with heme, any compound of iron complexed in a porphyrin (tetrapyrrole) ring.</Detail>
      <Keyword>Heme binding</Keyword>
      <Ontology_ID>GO:0020037</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with any metal ion.</Detail>
      <Keyword>Metal ion binding</Keyword>
      <Ontology_ID>GO:0046872</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the reduction of an aliphatic ring to yield an aromatic ring.</Detail>
      <Keyword>Aromatase activity</Keyword>
      <Ontology_ID>GO:0070330</Ontology_ID>
    </Funtion>
  </Function_List>
  <Mutation_List>
    <Muntion>
      <Position>418</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>34</Position>
      <Original>Pro</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>212</Position>
      <Original>Gly</Original>
      <Variation>Glu</Variation>
    </Muntion>
    <Muntion>
      <Position>478</Position>
      <Original>His</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>107</Position>
      <Original>Thr</Original>
      <Variation>Ile</Variation>
    </Muntion>
    <Muntion>
      <Position>26</Position>
      <Original>Arg</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>11</Position>
      <Original>Val</Original>
      <Variation>Met</Variation>
    </Muntion>
    <Muntion>
      <Position>297</Position>
      <Original>Ile</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>85</Position>
      <Original>Ala</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>120</Position>
      <Original>Phe</Original>
      <Variation>Ile</Variation>
    </Muntion>
    <Muntion>
      <Position>329</Position>
      <Original>Arg</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>300</Position>
      <Original>Ala</Original>
      <Variation>Gly</Variation>
    </Muntion>
    <Muntion>
      <Position>365</Position>
      <Original>Arg</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>28</Position>
      <Original>Arg</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>343</Position>
      <Original>Arg</Original>
      <Variation>Gly</Variation>
    </Muntion>
    <Muntion>
      <Position>373</Position>
      <Original>Gly</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>311</Position>
      <Original>Ser</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>486</Position>
      <Original>Ser</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>91</Position>
      <Original>Leu</Original>
      <Variation>Met</Variation>
    </Muntion>
    <Muntion>
      <Position>410</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>237</Position>
      <Original>Ala</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>94</Position>
      <Original>His</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>469</Position>
      <Original>Pro</Original>
      <Variation>Ala</Variation>
    </Muntion>
    <Muntion>
      <Position>231</Position>
      <Original>Leu</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>369</Position>
      <Original>Ile</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>324</Position>
      <Original>His</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>42</Position>
      <Original>Gly</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>169</Position>
      <Original>Gly</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>155</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>296</Position>
      <Original>Arg</Original>
      <Variation>Cys</Variation>
    </Muntion>
  </Mutation_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>The chemical reactions and pathways involving small molecules, any monomeric molecule of small relative molecular mass.</Detail>
      <Keyword>Small molecule metabolic process</Keyword>
      <Ontology_ID>GO:0044281</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways involving steroids, compounds with a 1,2,cyclopentanoperhydrophenanthrene nucleus.</Detail>
      <Keyword>Steroid metabolic process</Keyword>
      <Ontology_ID>GO:0008202</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that decreases the rate, frequency or extent of the chemical reactions and pathways involving organofluorine compounds, as carried out by individual cells.</Detail>
      <Keyword>Negative regulation of cellular organofluorine metabolic process</Keyword>
      <Ontology_ID>GO:0090350</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways involving a xenobiotic compound, a compound foreign to living organisms. Used of chemical compounds, e.g. a xenobiotic chemical, such as a pesticide.</Detail>
      <Keyword>Xenobiotic metabolic process</Keyword>
      <Ontology_ID>GO:0006805</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways involving coumarins, compounds derived from the phenylacrylic skeleton of cinnamic acids.</Detail>
      <Keyword>Coumarin metabolic process</Keyword>
      <Ontology_ID>GO:0009804</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process of removing one or more methyl groups from a molecule, involving the oxidation (i.e. electron loss) of one or more atoms in the substrate.</Detail>
      <Keyword>Oxidative demethylation</Keyword>
      <Ontology_ID>GO:0070989</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways involving isoquinoline alkaloids, alkaloid compounds that contain bicyclic N-containing aromatic rings and are derived from a 3,4-dihydroxytyramine (dopamine) precursor that undergoes a Schiff base addition with aldehydes of different origin.</Detail>
      <Keyword>Isoquinoline alkaloid metabolic process</Keyword>
      <Ontology_ID>GO:0033076</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways resulting in the breakdown of a drug, a substance used in the diagnosis, treatment or prevention of a disease.</Detail>
      <Keyword>Drug catabolic process</Keyword>
      <Ontology_ID>GO:0042737</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops or reduces the rate or extent of binding, the selective interaction of a molecule with one or more specific sites on another molecule.</Detail>
      <Keyword>Negative regulation of binding</Keyword>
      <Ontology_ID>GO:0051100</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways resulting in the breakdown of alkaloids, nitrogen containing natural products not otherwise classified as peptides, nonprotein amino acids, amines, cyanogenic glycosides, glucosinolates, cofactors, phytohormones or primary metabolites (such as purine or pyrimidine bases).</Detail>
      <Keyword>Alkaloid catabolic process</Keyword>
      <Ontology_ID>GO:0009822</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways involving monoterpenoid compounds, terpenoids having a C10 skeleton.</Detail>
      <Keyword>Monoterpenoid metabolic process</Keyword>
      <Ontology_ID>GO:0016098</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A metabolic process that results in the removal or addition of one or more electrons to or from a substance, with or without the concomitant removal or addition of a proton or protons.</Detail>
      <Keyword>Oxidation-reduction process</Keyword>
      <Ontology_ID>GO:0055114</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <Molecule_Seq>
    <Protein_Seq>MGLEALVPLAVIVAIFLLLVDLMHRRQRWAARYPPGPLPLPGLGNLLHVDFQNTPYCFDQLRRRFGDVFSLQLAWTPVVVLNGLAAVREALVTHGEDTADRPPVPITQILGFGPRSQGVFLARYGPAWREQRRFSVSTLRNLGLGKKSLEQWVTEEAACLCAAFANHSGRPFRPNGLLDKAVSNVIASLTCGRRFEYDDPRFLRLLDLAQEGLKEESGFLREVLNAVPVLLHIPALAGKVLRFQKAFLTQLDELLTEHRMTWDPAQPPRDLTEAFLAEMEKAKGNPESSFNDENLRIVVADLFSAGMVTTSTTLAWGLLLMILHPDVQRRVQQEIDDVIGQVRRPEMGDQAHMPYTTAVIHEVQRFGDIVPLGVTHMTSRDIEVQGFRIPKGTTLITNLSSVLKDEAVWEKPFRFHPEHFLDAQGHFVKPEAFLPFSAGRRACLGEPLARMELFLFFTSLLQHFSFSVPTGQPRPSHHGVFAFLVSPSPYELCAVPR</Protein_Seq>
    <DNA_Seq>ATGGGGCTAGAAGCACTGGTGCCCCTGGCCGTGATAGTGGCCATCTTCCTGCTCCTGGTGGACCTGATGCACCGGCGCCAACGCTGGGCTGCACGCTACCCACCAGGCCCCCTGCCACTGCCCGGGCTGGGCAACCTGCTGCATGTGGACTTCCAGAACACACCATACTGCTTCGACCAGTTGCGGCGCCGCTTCGGGGACGTGTTCAGCCTGCAGCTGGCCTGGACGCCGGTGGTCGTGCTCAATGGGCTGGCGGCCGTGCGCGAGGCGCTGGTGACCCACGGCGAGGACACCGCCGACCGCCCGCCTGTGCCCATCACCCAGATCCTGGGTTTCGGGCCGCGTTCCCAAGGGGTGTTCCTGGCGCGCTATGGGCCCGCGTGGCGCGAGCAGAGGCGCTTCTCCGTGTCCACCTTGCGCAACTTGGGCCTGGGCAAGAAGTCGCTGGAGCAGTGGGTGACCGAGGAGGCCGCCTGCCTTTGTGCCGCCTTCGCCAACCACTCCGGACGCCCCTTTCGCCCCAACGGTCTCTTGGACAAAGCCGTGAGCAACGTGATCGCCTCCCTCACCTGCGGGCGCCGCTTCGAGTACGACGACCCTCGCTTCCTCAGGCTGCTGGACCTAGCTCAGGAGGGACTGAAGGAGGAGTCGGGCTTTCTGCGCGAGGTGCTGAATGCTGTCCCCGTCCTCCTGCATATCCCAGCGCTGGCTGGCAAGGTCCTACGCTTCCAAAAGGCTTTCCTGACCCAGCTGGATGAGCTGCTAACTGAGCACAGGATGACCTGGGACCCAGCCCAGCCCCCCCGAGACCTGACTGAGGCCTTCCTGGCAGAGATGGAGAAGGCCAAGGGGAACCCTGAGAGCAGCTTCAATGATGAGAACCTGCGCATAGTGGTGGCTGACCTGTTCTCTGCCGGGATGGTGACCACCTCGACCACGCTGGCCTGGGGCCTCCTGCTCATGATCCTACATCCGGATGTGCAGCGCCGTGTCCAACAGGAGATCGACGACGTGATAGGGCAGGTGCGGCGACCAGAGATGGGTGACCAGGCTCACATGCCCTACACCACTGCCGTGATTCATGAGGTGCAGCGCTTTGGGGACATCGTCCCCCTGGGTATGACCCATATGACATCCCGTGACATCGAAGTACAGGGCTTCCGCATCCCTAAGGGAACGACACTCATCACCAACCTGTCATCGGTGCTGAAGGATGAGGCCGTCTGGGAGAAGCCCTTCCGCTTCCACCCCGAACACTTCCTGGATGCCCAGGGCCACTTTGTGAAGCCGGAGGCCTTCCTGCCTTTCTCAGCAGGCCGCCGTGCATGCCTCGGGGAGCCCCTGGCCCGCATGGAGCTCTTCCTCTTCTTCACCTCCCTGCTGCAGCACTTCAGCTTCTCGGTGCCCACTGGACAGCCCCGGCCCAGCCACCATGGTGTCTTTGCTTTCCTGGTGAGCCCATCCCCCTATGAGCTTTGTGCTGTGCCCCGCTAGAATGGGGTACCTAGTCCCCAGCCTGCTCCTAGCCCAGAGGCTCTAATGTACAATAAAGCAATGTGGTAGTTCC</DNA_Seq>
  </Molecule_Seq>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Microsome</CellLocal>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Membrane Associated</CellLocal>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Endoplasmic reticulum</CellLocal>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>CYP2D6</Gene_Name>
    <Gene_Alias>CYP2DL1</Gene_Alias>
    <Gene_ID>1565</Gene_ID>
    <Genbank_ACCN>M20403</Genbank_ACCN>
    <Protein_ACCN>AAA52153</Protein_ACCN>
    <HGNC_ID>2625</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/1565</Gene_URL>
    <EMBL_ID>ENSG00000100197</EMBL_ID>
  </Gene>
  <Disease_List>
    <Disease>
      <Disease_Name>Resistance to Imipramine in the Treatment of Depression</Disease_Name>
      <Disease_Detail>Resistance in the Treatment of Depression</Disease_Detail>
      <Disease_DB>RSS017</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/resistance_to_imipramine_in_the_treatment_of_depression?search=CYP2D6#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Imipramine Toxicity</Disease_Name>
      <Disease_Detail>Imipramine Toxicity</Disease_Detail>
      <Disease_DB>IMP015</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/imipramine_toxicity?search=CYP2D6#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Resistance to Clomipramine in the Treatment of Depression</Disease_Name>
      <Disease_Detail>Resistance in the Treatment of Depression</Disease_Detail>
      <Disease_DB>RSS019</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/resistance_to_clomipramine_in_the_treatment_of_depression?search=CYP2D6#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Parkinson's Disease</Disease_Name>
      <Disease_Detail>Parkinson's Disease</Disease_Detail>
      <Disease_DB>PRK002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/parkinsons_disease?search=CYP2D6#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Serotonin Syndrome</Disease_Name>
      <Disease_Detail>Serotonin Syndrome</Disease_Detail>
      <Disease_DB>SRT004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/serotonin_syndrome?search=CYP2D6#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Debrisoquine Sensitivity</Disease_Name>
      <Disease_Detail>Debrisoquine Sensitivity</Disease_Detail>
      <Disease_DB>DBR001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/debrisoquine_sensitivity?search=CYP2D6#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Resistance to Amitriptyline in the Treatment of Depression</Disease_Name>
      <Disease_Detail>Resistance in the Treatment of Depression</Disease_Detail>
      <Disease_DB>RSS020</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/resistance_to_amitriptyline_in_the_treatment_of_depression?search=CYP2D6#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Cytochrome P450 2d6 Variant</Disease_Name>
      <Disease_Detail>Cytochrome P450 2d6 Variant</Disease_Detail>
      <Disease_DB>CYT018</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/cytochrome_p450_2d6_variant?search=CYP2D6#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Tardive Dyskinesia</Disease_Name>
      <Disease_Detail>Tardive Dyskinesia</Disease_Detail>
      <Disease_DB>TRD006</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/tardive_dyskinesia?search=CYP2D6#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Amitriptyline Toxicity</Disease_Name>
      <Disease_Detail>Amitriptyline Toxicity</Disease_Detail>
      <Disease_DB>AMT004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/amitriptyline_toxicity?search=CYP2D6#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Susceptibility to Adverse Reaction Due to Nortriptyline Treatment</Disease_Name>
      <Disease_Detail>Susceptibility to Adverse Reaction</Disease_Detail>
      <Disease_DB>SSC037</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/susceptibility_to_adverse_reaction_due_to_nortriptyline_treatment?search=CYP2D6#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Neuroleptic Malignant Syndrome</Disease_Name>
      <Disease_Detail>Neuroleptic Malignant Syndrome</Disease_Detail>
      <Disease_DB>NRL004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/neuroleptic_malignant_syndrome?search=CYP2D6#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Multiple Chemical Sensitivity</Disease_Name>
      <Disease_Detail>Multiple Chemical Sensitivity</Disease_Detail>
      <Disease_DB>MLT001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/multiple_chemical_sensitivity?search=CYP2D6#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Nortriptyline Toxicity</Disease_Name>
      <Disease_Detail>Nortriptyline Toxicity</Disease_Detail>
      <Disease_DB>NRT012</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/nortriptyline_toxicity?search=CYP2D6#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Susceptibility to Adverse Reaction Due to Imipramine Treatment</Disease_Name>
      <Disease_Detail>Susceptibility to Adverse Reaction</Disease_Detail>
      <Disease_DB>SSC041</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/susceptibility_to_adverse_reaction_due_to_imipramine_treatment?search=CYP2D6#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Breast Cancer</Disease_Name>
      <Disease_Detail>Breast Cancer</Disease_Detail>
      <Disease_DB>BRS047</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/breast_cancer?search=CYP2D6#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Susceptibility to Adverse Reaction Due to Trimipramine Treatment</Disease_Name>
      <Disease_Detail>Susceptibility to Adverse Reaction</Disease_Detail>
      <Disease_DB>SSC033</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/susceptibility_to_adverse_reaction_due_to_trimipramine_treatment?search=CYP2D6#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Schizophrenia</Disease_Name>
      <Disease_Detail>Schizophrenia</Disease_Detail>
      <Disease_DB>SCH015</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/schizophrenia?search=CYP2D6#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Susceptibility to Adverse Reaction Due to Antipsychotics Treatment</Disease_Name>
      <Disease_Detail>Susceptibility to Adverse Reaction</Disease_Detail>
      <Disease_DB>SSC028</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/susceptibility_to_adverse_reaction_due_to_antipsychotics_treatment?search=CYP2D6#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Susceptibility to Adverse Reaction Due to Clomipramine Treatment</Disease_Name>
      <Disease_Detail>Susceptibility to Adverse Reaction</Disease_Detail>
      <Disease_DB>SSC045</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/susceptibility_to_adverse_reaction_due_to_clomipramine_treatment?search=CYP2D6#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hypersomnia</Disease_Name>
      <Disease_Detail>Hypersomnia</Disease_Detail>
      <Disease_DB>HYP263</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hypersomnia?search=CYP2D6#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Clomipramine Toxicity</Disease_Name>
      <Disease_Detail>Clomipramine Toxicity</Disease_Detail>
      <Disease_DB>CLM003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/clomipramine_toxicity?search=CYP2D6#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Pseudobulbar Affect</Disease_Name>
      <Disease_Detail>Pseudobulbar Affect</Disease_Detail>
      <Disease_DB>PSD088</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/pseudobulbar_affect?search=CYP2D6#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Resistance to Venlafaxine in the Treatment of Depression</Disease_Name>
      <Disease_Detail>Resistance in the Treatment of Depression</Disease_Detail>
      <Disease_DB>RSS011</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/resistance_to_venlafaxine_in_the_treatment_of_depression?search=CYP2D6#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Trimipramine Toxicity</Disease_Name>
      <Disease_Detail>Trimipramine Toxicity</Disease_Detail>
      <Disease_DB>TRM019</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/trimipramine_toxicity?search=CYP2D6#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Resistance to Tamoxifene in Breast Cancer</Disease_Name>
      <Disease_Detail>Resistance in the Treatment of Depression</Disease_Detail>
      <Disease_DB>RSS013</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/resistance_to_tamoxifene_in_breast_cancer?search=CYP2D6#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Codeine Toxicity</Disease_Name>
      <Disease_Detail>Codeine Toxicity</Disease_Detail>
      <Disease_DB>CDN003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/codeine_toxicity?search=CYP2D6#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Drug-Induced Hepatitis</Disease_Name>
      <Disease_Detail>Drug-Induced Hepatitis</Disease_Detail>
      <Disease_DB>DRG002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/drug_induced_hepatitis?search=CYP2D6#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Colorectal Cancer</Disease_Name>
      <Disease_Detail>Colorectal Cancer</Disease_Detail>
      <Disease_DB>CLR023</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/colorectal_cancer?search=CYP2D6#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Codeine Sensitivity</Disease_Name>
      <Disease_Detail>Codeine Sensitivity</Disease_Detail>
      <Disease_DB>CDN001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/codeine_sensitivity?search=CYP2D6#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Susceptibility to Adverse Reaction Due to Codeine Treatment</Disease_Name>
      <Disease_Detail>Susceptibility to Adverse Reaction</Disease_Detail>
      <Disease_DB>SSC043</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/susceptibility_to_adverse_reaction_due_to_codeine_treatment?search=CYP2D6#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Susceptibility to Adverse Reaction Due to Amitriptyline Treatment</Disease_Name>
      <Disease_Detail>Susceptibility to Adverse Reaction</Disease_Detail>
      <Disease_DB>SSC029</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/susceptibility_to_adverse_reaction_due_to_amitriptyline_treatment?search=CYP2D6#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Resistance to Trimipramine in the Treatment of Depression</Disease_Name>
      <Disease_Detail>Resistance in the Treatment of Depression</Disease_Detail>
      <Disease_DB>RSS012</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/resistance_to_trimipramine_in_the_treatment_of_depression?search=CYP2D6#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Antipsychotics Toxicity</Disease_Name>
      <Disease_Detail>Antipsychotics Toxicity</Disease_Detail>
      <Disease_DB>ANT059</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/antipsychotics_toxicity?search=CYP2D6#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Susceptibility to Adverse Reaction Due to Venlafaxine Treatment</Disease_Name>
      <Disease_Detail>Susceptibility to Adverse Reaction</Disease_Detail>
      <Disease_DB>SSC034</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/susceptibility_to_adverse_reaction_due_to_venlafaxine_treatment?search=CYP2D6#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Resistance to Nortripilline in the Treatment of Depression</Disease_Name>
      <Disease_Detail>Resistance in the Treatment of Depression</Disease_Detail>
      <Disease_DB>RSS016</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/resistance_to_nortripilline_in_the_treatment_of_depression?search=CYP2D6#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Venlafaxine Toxicity</Disease_Name>
      <Disease_Detail>Venlafaxine Toxicity</Disease_Detail>
      <Disease_DB>VNL002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/venlafaxine_toxicity?search=CYP2D6#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Autoimmune Hepatitis</Disease_Name>
      <Disease_Detail>Autoimmune Hepatitis</Disease_Detail>
      <Disease_DB>ATM011</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/autoimmune_hepatitis?search=CYP2D6#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>Crystal Structure of Human Cytochrome P450 2D6</PDB_Title>
      <PDB_ID>2F9Q</PDB_ID>
      <Resolution>3.0</Resolution>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of human cytochrome P450 2D6.</PubMed_Title>
      <Author>Rowland P, et al.</Author>
      <Journal>J Biol Chem. 2006 Mar 17;281(11):7614-22.</Journal>
      <PubMed_ID>16352597</PubMed_ID>
    </PDB>
  </PDB_List>
  <Network_List>
    <Network>
      <Pathway_ID>ko00982</Pathway_ID>
      <Pathway_Title>Drug metabolism - cytochrome P450</Pathway_Title>
      <Pathway_Class>Metabolism</Pathway_Class>
      <Pathway_Subclass>Xenobiotics biodegradation and metabolism</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko00982</Pathway_ID>
      <Pathway_Title>Drug metabolism - cytochrome P450</Pathway_Title>
      <Pathway_Class>Metabolism</Pathway_Class>
      <Pathway_Subclass>Xenobiotics biodegradation and metabolism</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko00982</Pathway_ID>
      <Pathway_Title>Drug metabolism - cytochrome P450</Pathway_Title>
      <Pathway_Class>Metabolism</Pathway_Class>
      <Pathway_Subclass>Xenobiotics biodegradation and metabolism</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko00982</Pathway_ID>
      <Pathway_Title>Drug metabolism - cytochrome P450</Pathway_Title>
      <Pathway_Class>Metabolism</Pathway_Class>
      <Pathway_Subclass>Xenobiotics biodegradation and metabolism</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko00982</Pathway_ID>
      <Pathway_Title>Drug metabolism - cytochrome P450</Pathway_Title>
      <Pathway_Class>Metabolism</Pathway_Class>
      <Pathway_Subclass>Xenobiotics biodegradation and metabolism</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko00982</Pathway_ID>
      <Pathway_Title>Drug metabolism - cytochrome P450</Pathway_Title>
      <Pathway_Class>Metabolism</Pathway_Class>
      <Pathway_Subclass>Xenobiotics biodegradation and metabolism</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko00980</Pathway_ID>
      <Pathway_Title>Metabolism of xenobiotics by cytochrome P450</Pathway_Title>
      <Pathway_Class>Metabolism</Pathway_Class>
      <Pathway_Subclass>Xenobiotics biodegradation and metabolism</Pathway_Subclass>
    </Network>
  </Network_List>
  <Fold>
    <CATH_Class>Mainly alpha</CATH_Class>
    <CATH_URL>http://www.cathdb.info/pdb/2f9q</CATH_URL>
  </Fold>
  <AllostericSite_List>
    <AllostericSite>
      <Site_Reference>Modi S, et al. Biochemistry. 1997,36(15):4461-4470.</Site_Reference>
      <Site_Type>Protein-induced</Site_Type>
      <PubMed_ID>9109653</PubMed_ID>
    </AllostericSite>
  </AllostericSite_List>
  <Enzyme_Nomenclature_List>
    <Enzyme_Nomenclature>
      <Enzyme_DB_ID>1.14.14.1</Enzyme_DB_ID>
      <Enzyme_DB_URL>http://www.chem.qmul.ac.uk/iubmb/enzyme/EC1/14/14/1.html</Enzyme_DB_URL>
    </Enzyme_Nomenclature>
  </Enzyme_Nomenclature_List>
  <Create_Date>2012-05-31</Create_Date>
</Organism_Record>